Transcriptomic profiling of Aurora Kinase B inhibition in lupus-prone mice

Lupus nephritis (LN) is one of the most common and severe complications of systemic lupus erythematosus (SLE). Multitarget therapy (MT) has demonstrated a 20% higher rate of complete remission (CR) compared to conventional treatments for LN. Using a signature-based approach for drug repurposing, we identified and validated that the specific Aurora Kinase B (AURKB) inhibitor AZD1152 exhibits therapeutic efficacy comparable to that of MT therapy. To elucidate the therapeutic mechanism of AZD1152, we conducted transcriptome sequencing on renal tissues from MRL/lpr mice treated with AZD1152 and control vehicle. , Bulk RNA-seq was performed on renal tissues from four MRL/lpr mice treated with AZD1152 and three MRL/lpr mice treated with vehicle.